Acurx Pharmaceuticals (NASDAQ: ACXP) has been granted a new patent by the U.S. Patent and Trademark Office (USPTO) covering DNA Polymerase IIIC inhibitors including compositions of matter, methods of use, and pharmaceutical compositions.
According to Acurx Pharmaceuticals, the company has secured four U.S. patents, along with granted patents in Israel, Japan, India, and Australia, all of which protect key aspects of its ACX 375C program targeting DNA Polymerase IIIC. Additional country level patent applications remain under review.
In a statement, Robert J. DeLuccia, executive chairman of Acurx Pharmaceuticals, commented,” Achieving this new patent extends our patent estate protection as we further develop our innovative, AI-supported drug discovery platform. We believe Acurx Pharmaceuticals’ inventions have the potential to create a transformational shift in the treatment paradigm for serious and potentially life-threatening infections. Recently presented microbiome selectivity data on representative novel compounds from our preclinical pipeline provides initial evidence that microbiome selectivity, when compared to the comparator antibiotic, linezolid, may be a class effect.”
